183 related articles for article (PubMed ID: 36126024)
1. Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States.
Geris JM; Spector LG; Pfeiffer RM; Limaye AP; Yu KJ; Engels EA
Cancer; 2022 Nov; 128(22):3985-3994. PubMed ID: 36126024
[TBL] [Abstract][Full Text] [Related]
2. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
Belga S; Hernandez C; Kabbani D; Cervera C
Transpl Infect Dis; 2024 Apr; 26(2):e14227. PubMed ID: 38180285
[TBL] [Abstract][Full Text] [Related]
3. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
4. Increasing Proportion of High-risk Cytomegalovirus Donor-positive/Recipient-negative Serostatus in Solid Organ Transplant Recipients.
Imlay H; Wagener MM; Vutien P; Perkins J; Singh N; Limaye AP
Transplantation; 2023 Apr; 107(4):988-993. PubMed ID: 36173456
[TBL] [Abstract][Full Text] [Related]
5. Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation.
Belga S; MacDonald C; Chiang D; Kabbani D; Shojai S; Abraldes JG; Cervera C
Clin Infect Dis; 2021 Mar; 72(5):845-852. PubMed ID: 32025704
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus transmission in mismatched solid organ transplant recipients: Are factors other than anti-viral prophylaxis at play?
Hernandez C; Mabilangan C; Burton C; Doucette K; Preiksaitis J
Am J Transplant; 2021 Dec; 21(12):3958-3970. PubMed ID: 34174153
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
9. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
11. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
13. Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors.
Belga S; Hussain S; Avery RK; Nauroz Z; Durand CM; King EA; Massie A; Segev DL; Connor AE; Bush EL; Levy RD; Shah P; Werbel WA
J Heart Lung Transplant; 2024 Apr; 43(4):615-625. PubMed ID: 38061469
[TBL] [Abstract][Full Text] [Related]
14. Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients.
Vutien P; Perkins J; Biggins SW; Reyes J; Imlay H; Limaye AP
Liver Transpl; 2021 Sep; 27(9):1302-1311. PubMed ID: 33687777
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
16. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Vernooij RW; Michael M; Ladhani M; Webster AC; Strippoli GF; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2024 May; 5(5):CD003774. PubMed ID: 38700045
[TBL] [Abstract][Full Text] [Related]
17. Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (D-/R-).
Jorgenson MR; Descourouez JL; Yang DY; Stalter LN; Leverson GE; Parajuli S; Mandelbrot DA; Smith JA; Redfield RR
Transpl Infect Dis; 2021 Jun; 23(3):e13564. PubMed ID: 33449413
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
Cameron BM; Kennedy SE; Rawlinson WD; Mackie FE
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27704725
[TBL] [Abstract][Full Text] [Related]
19. Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.
Imlay H; Dumitriu Carcoana AO; Fisher CE; Wong B; Rakita RM; Fishbein DP; Limaye AP
Transpl Infect Dis; 2020 Jun; 22(3):e13255. PubMed ID: 32020736
[TBL] [Abstract][Full Text] [Related]
20. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.
Anderson-Smits C; Baker ER; Hirji I
Transpl Infect Dis; 2020 Dec; 22(6):e13396. PubMed ID: 32603496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
